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Abstract: Background: The marine-derived kinase inhibitor fascaplysin down-regulates the 
PI3K pathway in cancer cells. Since this pathway also plays an essential role in platelet 
signaling, we herein investigated the effect of fascaplysin on thrombosis. Methods: Fascaplysin 
effects on platelet activation, platelet aggregation and platelet-leukocyte aggregates (PLA) 
formation were analyzed by flow cytometry. Mouse dorsal skinfold chambers were used to 
determine in vivo the effect of fascaplysin on photochemically induced thrombus formation 
and tail-vein bleeding time. Results: Pre-treatment of platelets with fascaplysin reduced the 
activation of glycoprotein (GP)IIb/IIIa after protease-activated receptor-1-activating peptide 
(PAR-1-AP), adenosine diphosphate (ADP) and phorbol-12-myristate-13-acetate (PMA) 
stimulation, but did not markedly affect the expression of P-selectin. This was associated 
with a decreased platelet aggregation. Fascaplysin also decreased PLA formation after PMA 
but not PAR-1-AP and ADP stimulation. This may be explained by an increased expression 
of CD11b on leukocytes in PAR-1-AP- and ADP-treated whole blood. In the dorsal skinfold 
chamber model of photochemically induced thrombus formation, fascaplysin-treated mice 
revealed a significantly extended complete vessel occlusion time when compared to controls. 
Furthermore, fascaplysin increased the tail-vein bleeding time. Conclusion: Fascaplysin 
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exerts anti-thrombotic activity, which represents a novel mode of action in the pleiotropic 
activity spectrum of this compound. 
Keywords: fascaplysin; thrombosis; platelets; GPIIb/IIIa; P-selectin; leukocytes; CD11b; 
dorsal skinfold chamber 
 
1. Introduction 
Fascaplysin is a marine-derived kinase inhibitor that was originally isolated from the Fijian marine 
sponge Fascaplysinopsis [1]. Over the last decade, several studies suggested the application of this 
compound in cancer therapy, because it exerts multiple anti-tumor effects. For instance, fascaplysin  
is cytotoxic via intercalation into the DNA [2] and induction of apoptotic cell death by inhibition of  
cyclin-dependent-kinase-4/cyclin D1 (CDK4/D1) [1]. Moreover, fascaplysin inhibits the proliferation of 
human umbilical vein endothelial cells (HUVEC), suppresses VEGF expression and reduces capillary 
plexus formation in the chorioallantoic membrane model, indicating an anti-angiogenic activity [3,4]. 
Finally, Kumar et al. [5] recently reported that fascaplysin down-regulates PI3K/AKT/mTOR signaling 
in cancer cells. Noteworthy, this central pathway is not only essential for cell survival and cell growth, 
but also plays a crucial role in thrombus formation [6–9]. 
Thrombus formation is a complex process, which involves the interaction of soluble plasma 
components, platelets and leukocytes. The molecular mechanisms of platelet activation are strictly 
regulated by several phospho-regulated pathways, including PI3K/AKT signaling [10–13]. All PI3K 
isoforms are expressed in platelets and are responsible for the generation of phosphatidylinositol  
3,4,5-trisphosphate (PIP3) via phosphorylation of phosphatidylinositides in the plasma membrane [12]. 
This, in turn, stimulates protein kinase B (PKB/Akt) by a conformational switch, resulting in platelet 
activation [8,12,14]. 
Consequently, several surface proteins are up-regulated on platelets, including glycoprotein (GP)IIb/IIIa 
and P-selectin [15–17]. The activated form of GPIIb/IIIa recognizes RGD-containing glycoproteins, 
such as fibrinogen or vWF, which mediates platelet aggregation and effective hemostatic plug  
formation [18–20]. On the other hand, P-selectin binds to its counter-receptor P-selectin glycoprotein 
ligand (PSGL)-1 on leukocytes, resulting in the additional incorporation of platelet-leukocyte aggregates 
(PLA) in the newly developing thrombus [16,21,22]. 
Based on the important role of PI3K/AKT in platelet signaling and the observed inhibitory effect of 
fascaplysin on this pathway in cancer cells, we herein hypothesized that fascaplysin may exert potent 
anti-thrombotic activity. To test this hypothesis, we first examined in vitro the effect of the compound 
on platelet activation, platelet aggregation and PLA formation. Moreover, dorsal skinfold chambers in 
BALB/c mice were used to analyze in vivo the effect of fascaplysin on photochemically induced 
thrombus formation and tail-vein bleeding time. 
  




2.1. Effect of Fascaplysin on Platelet Viability and PI3K Signaling 
In a first set of experiments, we analyzed the effect of fascaplysin on platelet viability by flow 
cytometry. We found that fascaplysin doses up to 10 μM did not exert any toxic effects, whereas higher 
concentrations of 25 and 50 μM significantly reduced the viability of platelets (Figure 1A). Based on 
these results, we decided to use only fascaplysin doses up to 10 μM for all following in vitro assays to 
investigate the effects of the kinase inhibitor in a non-toxic dose range. 
 
 
Figure 1. Effect of fascaplysin on platelet viability and PI3K signaling. (A) Washed platelets 
(WP) were incubated with different concentrations of fascaplysin (black bars, n = 4) or 
vehicle dimethyl sulfoxide (DMSO), white bars, n = 4) for 0.5 h. Untreated platelets served 
as negative control (grey bars, n = 4). Platelet viability was assessed by flow cytometry.  
Data are given in % of vehicle. Mean ± SEM. * p < 0.05 vs. vehicle; (B,C) Western blot 
analysis of CDK4, p85 and α-tubulin expression in untreated human dermal microvascular 
endothelial cells (HDMEC) and WP. The shown Western blots are representative of 
experiments conducted in triplicate; (D) Western blot analysis of ERK, p-ERK and α-tubulin 
expression in WP, which were incubated with 10 μM fascaplysin for 0.5 h followed by 
stimulation with protease-activated receptor-1-activating peptide (PAR-1-AP). The shown 
Western blots are representative of experiments conducted in triplicate. 
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Fascaplysin suppresses PI3K signaling in cancer cells [5]. Moreover, fascaplysin has been shown to 
exert a strong inhibitory activity on CDK4 (IC50 = 0.35 μM) [1,4]. Besides, it also inhibits CDK6, for 
which encoding mRNA levels could be previously detected in platelets [23]. However, the inhibitory 
activity of fascaplysin on CDK6 is much lower (IC50 = 3.4 μM) [24]. Therefore, we decided to investigate 
the level of CDK4 and PI3K in washed platelets by Western blot analysis. Human dermal microvascular 
endothelial cells (HDMEC) served as controls. As expected, HDMEC expressed CDK4, because these 
cells have a nucleus and undergo a regular cyclin-controlled cell cycle. In contrast, platelets are 
anucleated, non-proliferating cells and, thus, they did not express CDK4 (Figure 1B). However, they 
exhibited a strong expression of the PI3K subunit p85 (Figure 1C). Therefore, we further analyzed 
whether fascaplysin reduces PI3K activity in platelets by assessing ERK phosphorylation, which is 
involved in downstream signaling of PI3K [25]. Our Western blot analyses revealed that washed platelets 
stimulated with protease-activated receptor-1-activating peptide (PAR-1-AP) exhibit an increased 
phosphorylation of ERK, indicating an activation of the PI3K pathway (Figure 1D). In contrast, 
treatment with 10 μM fascaplysin markedly reduced this phosphorylation (Figure 1D). 
2.2. Effect of Fascaplysin on Platelet Activation 
In a next step, we investigated the effect of fascaplysin on the expression of P-selectin and the 
activation of GPIIb/IIIa on platelets. For this purpose, washed platelets were incubated with concentrations 
of 2–10 μM fascaplysin, stimulated with the three agonists PAR-1-AP, adenosine diphosphate (ADP) 
and phorbol-12-myristate-13-acetate (PMA) and analyzed by flow cytometry. We found that fascaplysin 
does not affect the expression of P-selectin after PAR-1-AP and ADP stimulation (Figure 2A,C). 
Moreover, only the higher dose of 10 μM fascaplysin significantly inhibited P-selectin expression  
on PMA-activated platelets (Figure 2E). In contrast, fascaplysin markedly suppressed the  
activation of GPIIb/IIIa, as indicated by reduced PAC-1 binding levels after PAR-1-AP, ADP or PMA  
stimulation (Figure 2B,D,F). 
 
Figure 2. Cont. 




Figure 2. Effect of fascaplysin on agonist-induced P-selectin expression and GPIIb/IIIa 
activation. (A–F) WP were incubated with different concentrations of fascaplysin (black 
bars, n = 6) or vehicle (DMSO, white bars, n = 6) for 0.5 h following stimulation with  
PAR-1-AP (A,B), adenosine diphosphate (ADP) (B,D), or phorbol-12-myristate-13-acetate 
(PMA) (E,F). Data are given in % of vehicle. Unstimulated platelets served as negative 
control (grey bars, n = 6). Surface levels of PAC-1 (recognizing the activated form of 
glycoprotein (GP)IIb/IIIa) and P-selectin were assessed by flow cytometry. Mean ± SEM.  
* p < 0.05 vs. vehicle. 
2.3. Effect of Fascaplysin on Platelet Aggregation 
Based on our finding that fascaplysin suppresses the activation of GPIIb/IIIa, we next analyzed the 
aggregation capacity of fascaplysin-treated washed platelets. As expected, treatment of washed platelets 
with 10 μM fascaplysin resulted in an attenuated agonist-induced platelet aggregation (Figure 3A–C). 
2.4. Effect of Fascaplysin on PLA Formation 
Besides the main initiator P-selectin, PLA formation also depends on GPIIb/IIIa [26]. Based on our 
finding that fascaplysin markedly diminishes agonist-induced GPIIb/IIIa activation, we next analyzed 
by flow cytometry whether it also affects the interaction of platelets with leukocytes. We detected an 
increased number of platelets bound to leukocytes after PAR-1-AP and ADP stimulation, which, 
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however, was not influenced by fascaplysin pre-treatment. In contrast, fascaplysin caused a significant 
reduction of PMA-induced PLA formation (Figure 4A). 
 
Figure 3. Effect of fascaplysin on platelet aggregation. (A–C) Typical diagrams of 
aggregation results for WP, which were incubated with 10 μM fascaplysin (black lines) or 
vehicle (grey lines) for 0.5 h prior to the stimulation with PAR-1-AP (A); ADP (B); or  
PMA (C). 
 
Figure 4. Effect of fascaplysin on platelet-leukocyte aggregates (PLA) formation. (A–D) 
Whole blood was incubated with 10 μM fascaplysin (black bars, n = 6) or vehicle (DMSO, 
white bars, n = 6) for 0.5 h followed by stimulation with PAR-1-AP, ADP or PMA. Data are 
given in % of vehicle. Unstimulated whole blood served as negative control (grey bars,  
n = 6). Platelets bound to all leukocytes (A) or lymphocytes (B); monocytes (C) and 
granulocytes (D) were assessed by flow cytometry using double fluorescence staining 
(CD45/CD42b). Mean ± SEM. * p < 0.05 vs. vehicle. 
To gain further insights into this process, the binding of platelets to individual leukocyte subpopulations 
was analyzed (Figure 4B–D). In line with other studies [21,27], agonist stimulation was predominantly 
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observed in platelet-monocyte aggregates and platelet-granulocyte aggregates (Figure 4C,D). As expected, 
fascaplysin did not affect the binding of platelets to lymphocytes, monocytes or granulocytes following 
PAR-1-AP or ADP stimulation. However, the PMA-induced interaction of platelets with monocytes or 
granulocytes was significantly reduced in the presence of fascaplysin (Figure 4B–D). 
2.5. Effect of Fascaplysin on CD11b Expression on Leukocytes 
The formation of PLA is not only dependent on the activation of platelets, but also on the expression 
of leukocytic adhesion molecules. In this context, several studies reported that the leukocytic integrin 
Mac-1 (CD11b/CD18) mediates the binding to GPIIb/IIIa on platelets via fibrinogen bridging [28–30]. 
Accordingly, we further assessed the expression of CD11b on leukocytes by means of flow cytometry. 
We found that fascaplysin treatment markedly increases the levels of CD11b following PAR-1-AP or 
ADP stimulation. However, PMA-induced CD11b levels were not affected by exposure of the cells to 
fascaplysin (Figure 5A). The additional analysis of different leukocyte subpopulations revealed that only 
granulocytes showed a similar expression pattern, but not monocytes (Figure 5B,C). This indicates that 
fascaplysin-induced up-regulation of CD11b expression primarily occurs in granulocytes. 
Figure 5. Effect of fascaplysin on leukocytic CD11b expression. (A–C) Whole blood was 
incubated with 10 μM fascaplysin (black bars, n = 6) or vehicle (DMSO, white bars, n = 6) 
for 0.5 h followed by stimulation with PAR-1-AP, ADP or PMA. Data are given in % of vehicle. 
Unstimulated whole blood served as negative control (grey bars, n = 6). Expression of CD11b 
on all leukocytes (A), monocytes (B) and granulocytes (C) were assessed by flow cytometry 
using double fluorescence staining (CD45/CD11b). Mean ± SEM. * p < 0.05 vs. vehicle. 
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2.6. Effect of Fascaplysin on Thrombus Formation and Tail-Vein Bleeding Time 
Finally, we tested the anti-thrombotic activity of fascaplysin and heparin (positive control) in the 
dorsal skinfold chamber model of photochemically induced thrombus formation [31]. For this purpose, 
we analyzed postcapillary and collecting venules with a diameter of 15–25 μm, which exhibited 
comparable centerline red blood cell (RBC) velocities and wall shear rates (Table 1). As expected, 
heparin effectively increased complete vessel occlusion time and tail-vein bleeding time (Figure 6B,C), 
indicating that the present experimental setting is suitable to measure anti-thrombotic effects of test 
compounds. In line with our in vitro results, we detected a significantly prolonged complete vessel occlusion 
time within dorsal skinfold chambers of fascaplysin-treated mice when compared to vehicle-treated 
controls (Figure 6A,B). Moreover, treatment with fascaplysin also increased the tail-vein bleeding  
time (Figure 6C). 
Table 1. Diameter (μm), centerline red blood cell RBC velocity (μm/s) and wall shear rate 
(s−1) of postcapillary and collecting venules in dorsal skinfold chambers of fascaplysin  
(Fas)-treated (n = 6), heparin-treated (n = 3) and vehicle-treated (DMSO (n = 6) or saline  
(n = 3)) BALB/c mice directly before photochemically induced thrombus formation, as 
assessed by intravital fluorescence microscopy and computer-assisted image analysis. 
 Vehicle (DMSO) Fas Vehicle (Saline) Heparin 
diameter (μm) 16.7 ± 0.6 18.9 ± 0.7 20.9 ± 1.3 18.9 ± 1.6 
centerline RBC velocity (μm/s) 205.1 ± 62.2 230.9 ± 50.3 267.9 ± 45.9 219.3 ± 70.3
wall shear rate (s−1) 98.3 ± 25.9 97.7 ± 24.5 102.54 ± 32.8 92.8 ± 21.7
Mean ± SEM. 
Figure 6. Cont. 




Figure 6. Effect of fascaplysin and heparin on thrombus formation and tail-vein bleeding 
time. (A) Intravital fluorescent microscopic images of a postcapillary venule in the dorsal 
skinfold chamber of a vehicle-treated BALB/c mouse before (baseline) and after 
photochemically induced thrombus formation (asterisk). Blue-light epi-illumination with 
contrast enhancement by 5% fluorescein isothiocyanate (FITC)-labeled dextran 150,000. 
Scale bar: 50 μm. (B) Complete occlusion time of postcapillary and collecting venules upon 
photochemically induced thrombus formation in dorsal skinfold chambers of heparin-treated 
(upper black bar, n = 3), fascaplysin-treated (lower black bar, n = 6), and vehicle-treated 
BALB/c mice (upper white bar, saline, n = 3 and lower white bar, DMSO, n = 6), as assessed 
by intravital fluorescence microscopy. Mean ± SEM. * p < 0.05 vs. vehicle. (C) Tail-vein 
bleeding time of heparin-treated (upper black bar, n = 3), fascaplysin-treated (lower black 
bar, n = 6), and vehicle-treated BALB/c mice (upper white bar, saline, n = 3 and lower white 
bar, DMSO, n = 6). Mean ± SEM. * p < 0.05 vs. vehicle. 
3. Discussion 
The marine-derived kinase inhibitor fascaplysin targets fundamental cellular processes, such as 
proliferation, apoptosis and angiogenesis [1–3]. Accordingly, fascaplysin has been suggested as a 
candidate for the establishment of novel anti-tumor therapies [1,5]. For this purpose, it is, however, 
necessary to characterize in detail the activity spectrum of the compound. In this context, we herein 
demonstrate for the first time that fascaplysin affects the activation of platelets and their interaction with 
leukocytes, resulting in the suppression of hemostasis and thrombus formation. 
Recently, it has been demonstrated that exposure of human leukemia HL-60 cells to fascaplysin leads 
to an inhibition of all major proteins of the PI3K/AKT/mTOR pathway [5]. Moreover, it is well known 
that PI3K is a crucial regulator of thrombus formation [7,8,32]. In line with these studies, our results 
now show that fascaplysin reduces PI3K signaling in platelets and attenuates agonist-induced platelet 
aggregation. This may be explained by the fact that an attenuated PI3K activity deteriorates the affinity 
and avidity of GPIIb/IIIa for ligands, which is also called “inside-out signaling” [9,14]. However, we 
did not detect an effect of fascaplysin on the expression of P-selectin on PAR-1-AP- and ADP-stimulated 
platelets. This parallels findings of Kovacsovics et al. [33], demonstrating that treatment of platelets with 
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the specific PI3K inhibitor wortmannin results in decreased levels of activated GPIIb/IIIa without 
affecting P-selectin expression. 
Of interest, we additionally found that a higher dose of 10 μM fascaplysin significantly inhibited  
P-selectin expression on platelets stimulated by the strong PKC activator PMA. This indicates that 
fascaplysin also targets other kinases than PI3K. In this context, Anastassiadis et al. [34] tested 
fascaplysin against a panel of 300 kinases and detected an inhibitory effect of the compound on  
protein kinase C (PKC). PKC, which is downstream of phospholipase C (PLC), also mediates platelet 
aggregation by both GPIIb/IIIa activation and up-regulation of P-selectin expression. Hence, it may be 
assumed that besides the inhibition of PI3K a reduction of PKC activity contributed to the fascaplysin 
effects observed in the present study. 
The formation of PLA is a characteristic event during thrombus formation, which is mainly mediated 
by the binding of P-selectin on platelets to leukocytic PSGL-1 [16,22,35]. Besides, it has been reported 
that GPIIb/IIIa binds to the leukocytic integrin Mac-1 (CD11b/CD18) via fibrinogen as a bridging 
molecule [26,36,37]. The herein observed reduction of activated GPIIb/IIIa on fascaplysin-treated 
platelets suggests that the latter binding mechanism may have affected the formation of PLA. However, 
this was not the case when platelets were stimulated with PAR-1-AP or ADP. This interesting finding 
prompted us to further analyze the expression of CD11b on leukocytes. A small fraction of the total 
CD11b content is stored intracellularly and is rapidly up-regulated as a result of different types of  
stimuli [38]. Previous studies indicate that a reduced GPIIb/IIIa activation may represent such a  
stimulus [28,39]. In fact, Hu et al. [28] demonstrated that this leads to an enhanced level of CD11b on 
leukocytes, which, in turn, may compensate the down-regulation of activated GPIIb/IIIa. In line with 
this point of view, we measured increased levels of leukocytic CD11b in fascaplysin-treated whole blood 
after PAR-1-AP or ADP stimulation. 
In contrast, we detected a significantly lower rate of PLA following stimulation with the PKC 
activator PMA. This result may be caused by the aforementioned inhibitory effect of fascaplysin on 
PKC. In fact, PKC has been shown to mediate CD11b expression [38,40]. Accordingly, we did not detect 
a marked up-regulation of leukocytic CD11b expression in PMA-exposed whole blood when  
compared to PAR-1-AP- and ADP-treated blood. Thus, it is tempting to speculate that these lower  
levels of CD11b may have not been sufficient to compensate the fascaplysin-induced down-regulation 
of GPIIb/IIIa on platelets. The reduced formation of PLA may additionally be explained by the 
observation of Davenbeck et al. [16] that PSGL-1 is significantly decreased on human leukocytes 
following PMA stimulation. 
Finally, we confirmed the observed in vitro effects of fascaplysin on platelet aggregation and PLA 
formation in an in vivo model of photochemically induced thrombus formation [31,41]. Thrombus 
formation was induced in postcapillary and collecting venules in mouse dorsal skinfold chambers  
by administration of fluorescein isothiocyanate (FITC)-labeled dextran and transmural blue light 
exposure, which results in endothelial injury by local generation of reactive oxygen species [41]. 
Noteworthy, the microvessels of fascaplysin-treated and vehicle-treated animals did not exhibit any 
differences in microhemodynamic parameters, indicating that thrombus formation could be analyzed in 
both groups under comparable conditions. In accordance to our in vitro results we found that complete 
vessel occlusion time was significantly prolonged by treatment with fascaplysin. In contrast to other 
anti-platelet agents, such as aegyptin, dipetalodipin and triplatin [42,43], fascaplysin further affected 
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primary hemostasis during tail-vein bleeding. Moreover, fascaplysin showed a lower anti-thrombotic 
efficiency in our in vivo experiments when compared to heparin. Therefore, this compound may not be 
suitable as an anti-thrombotic drug for future clinical use. However, its anti-thrombotic activity should 
be considered as a potential side effect when using fascaplysin as an anti-cancer agent. 
In summary, the present study demonstrates that fascaplysin reduces GPIIb/IIIa activation and 
aggregation of platelets. This prevents thrombus formation and increases bleeding time. These results 
indicate for the first time that fascaplysin exerts anti-thrombotic activity, which represents a novel mode 
of action in the pleiotropic activity spectrum of this marine-derived kinase inhibitor. 
4. Experimental Section 
4.1. Chemical and Biological Reagents 
Fascaplysin was purchased from Santa Cruz Inc. (Heidelberg, Germany), calcein-AM from 
Molecular Probes (Eugene, OR, USA), heparin from Braun (Melsungen, Germany), ADP sodium salt, 
PAR-1-AP, PMA, dimethyl sulfoxide (DMSO), and FITC-labeled dextran 150,000 from Sigma-Aldrich 
(München, Germany), ketamine (Ursotamin®) from Pharmacia GmbH (Erlangen, Germany), xylazine 
(Rompun®) from Bayer (Leverkusen, Germany), and Endothelial Cell Basal Medium (C-22210) from 
PromoCell (Heidelberg, Germany). 
4.2. Antibodies 
The antibodies anti-CD11b (555388), anti-CD45 (3325829), anti-CD42b (555473), anti-CD62P 
(555524), anti-GPIIb/IIIa (PAC-1) (340507), anti-PI3K (p85) (610045) and IgG1-κ isotype control 
(555749) were purchased from BD Biosciences (Heidelberg, Germany). The antibodies phospho  
(p)-ERK (50011) and ERK (115799) were purchased from abcam (Cambridge, UK). The antibody  
α-tubulin (T6199) was purchased from Sigma-Aldrich (München, Germany). The antibody CDK4  
(C-22) was purchased from Santa Cruz Inc. (Heidelberg, Germany). 
4.3. Endothelial Cell Culture 
HDMEC were purchased from PromoCell and cultivated in Endothelial Cell Basal Medium at  
37 °C under a humidified 95% to 5% (v/v) mixture of air and CO2. Cells were passaged at a split ratio 
of 1:3 after reaching confluence. 
4.4. Ethics Statement 
For the isolation of platelet rich plasma (PRP), platelets and leukocytes, venous blood was drawn 
from six healthy volunteers after obtaining their written informed consent, and with the approval of the 
local ethics review board. 
4.5. Preparation of Washed Platelets 
Washed platelets were prepared as previously described [44]. Briefly, venous blood from six healthy 
voluntary donors was drawn into plastic syringes containing 0.1 volume of 3.2% trisodium citrate and 
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centrifuged at 100× g for 20 min at room temperature. The supernatant (PRP) was collected and 
centrifuged at 2200× g for 3 min. Subsequently, the supernatant was discarded and the pellet was washed 
twice in a cation-free HEPES-Tyrode buffer (pH 6.5) containing 1 mM EGTA. Afterwards, the pellet 
was resuspended in HEPES-Tyrode buffer (pH 7.4) containing 1.25 mM CaCl2 and 6.25 mg/mL BSA. 
Platelets were counted and adjusted to the concentration of 3 × 108 platelets/mL. 
4.6. Western Blot Analysis 
Protein levels of CDK4 and p85 were analyzed in untreated HDMEC and washed platelets. In 
additional experiments, washed platelets were treated for 30 min with different concentrations of 
fascaplysin or vehicle (DMSO) and then stimulated with PAR-1-AP (2.5 μM) for 5 min. The cells were 
centrifuged for 3 min by 4 °C and lysed on ice for 10 min in lysis buffer (RIPA buffer: 50 mM Tris-HCl, 
pH 7.2, 0.15 M NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0% sodium deoxycholate, and 
phosphatase inhibitor). Cell extracts were separated through a 10% SDS polyacrylamide gel and 
immunoblotted with specific antibodies. Protein expression was visualized by luminol-enhanced 
chemiluminescence (ECL; GE-Healthcare, Freiburg, Germany) and exposure of the membranes to a blue 
light sensitive autoradiography film (Hyperfilm ECL, GE-Healthcare, Freiburg, Germany). 
4.7. Platelet Aggregation 
Platelet aggregation was measured using a Born aggregometer (APACT 4SPlus, Rolf Greiner 
Biochemica, Flacht, Germany) at 37 °C under stirring conditions (700–1000 U/min). Aliquots of 180 μL 
washed platelets or HEPES-Tyrode buffer (pH 7.4) were incubated with the indicated concentrations  
of fascaplysin or vehicle (DMSO) for 30 min at 37 °C. Fascaplysin and DMSO were prediluted in 
HEPES-Tyrode buffer (pH 7.4) to lower the DMSO concentration. After incubation, HEPES-Tyrode 
buffer (pH 7.4) was used to calibrate the aggregometer to 0% before measuring and unstimulated washed 
platelets were used to calibrate up to 100% aggregation. Vehicle measuring was performed in all repeats. 
Washed platelets were stimulated with the agonists 2.5 μM PAR-1-AP, 10 μM ADP or 100 ng/mL PMA 
and change in light transmission was measured for 5 min. 
4.8. PLA 
PLA were induced as previously described [21]. Briefly, venous blood from six healthy human donors 
was drawn into plastic syringes containing 0.1 volume of 3.2% trisodium citrate. Subsequently, 10 μL 
blood was added to 40 μL of HEPES-Tyrode buffer (pH 7.4), containing appropriate concentrations of 
phycoerythrin (PE)-labeled anti-PE-CD42b and FITC-labeled anti-CD45 antibodies. The samples were 
treated with the indicated concentrations of fascaplysin or vehicle (DMSO) and incubated under static 
conditions for 15 min. After stimulation with ADP (10 μM), PMA (100 ng/mL) or PAR-1-AP (2.5 μM) 
for 20 min, the samples were fixed by adding 1% formalin (300 μL) and analyzed by flow cytometry. 
4.9. Flow Cytometry 
The viability of washed platelets was analyzed by flow cytometry, as previously described [45].  
For this purpose, washed platelets were treated for 30 min with different concentrations of fascaplysin 
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or vehicle (DMSO). Subsequently, 1 μL of calcein-AM (8 μM) and saturating concentrations of  
PE-labeled anti-CD42b antibody were added to 40 μL of washed platelets and incubated for 0.5 h.  
The appearance of double-colored events was then determined in a FACScan flow cytometer (Becton 
Dickinson, San Jose, CA, USA) using CellQuest software. 
Moreover, washed platelets were treated for 30 min with different concentrations of fascaplysin or 
vehicle (DMSO) followed by ADP-stimulation (10 μM), PMA (100 ng/mL) or PAR-1-AP-stimulation 
(2.5 μM) for 5 min. Aliquots (10 μL) of washed platelets were incubated with saturating concentrations 
of FITC-labeled anti-PAC-1 antibody, PE-labeled anti-CD62P (P-selectin) antibody or control antibody 
(isotype control) for 0.5 h. Afterwards the aliquots were fixed in 1% formalin for 10 min at 4 °C and 
were analyzed by flow cytometry. The fluorescence of 50,000 platelets was analyzed in the FACScan 
flow cytometer (Becton Dickinson, San Jose, CA, USA) using CellQuest software. The expression of 
activated GPIIb/IIIa and P-selectin was determined by analyzing the mean fluorescence intensity in the 
FL2 channel. 
In a subset of experiments, double fluorescence staining was performed in whole blood to analyze 
PLA as previously described [21]. Briefly, samples were analyzed in the FACScan flow cytometer using 
the CellQuest software. For the analysis, a quadrant was set in the dot plot of respective channels on 
non-stimulated platelets. The appearance of double-colored events in the upper right quadrant was 
determined. Then, CD45-labeled lymphocytes, monocytes and granulocytes were separately gated 
according to their size and granularity and the mean fluorescence intensity of PE-labeled anti-CD42b 
was analyzed. 
In addition, CD11b expression was determined as mean fluorescence intensity (MFI) in CD45-labeled 
total leukocytes, monocytes or granulocytes. 
4.10. Animals 
BALB/c mice with a body weight of 20–25 g were used for the experiments. They were housed in a 
temperature-controlled environment under a 12 h/12 h light-dark cycle and received standard pellet food 
(Altromin, Lage, Germany) and water ad libitum. All experiments were approved by the local 
governmental animal care committee (Landesamt für Verbraucherschutz, Abteilung C Lebensmittel- und 
Veterinärwesen, Saarbrücken, Germany; Permit Number: 15/2014) and were conducted in accordance 
with the European legislation on protection of animals (Guide line 2010/63/EU) and the NIH Guidelines 
for the Care and Use of Laboratory Animals. 
4.11. Photochemically Induced Thrombus Formation 
Mouse dorsal skinfold chambers were used to investigate in vivo the effect of fascaplysin on 
photochemically induced thrombus formation [31]. For this purpose, 18 BALB/c mice were anesthetized 
with an intraperitoneal injection (i.p.) of 75 mg/kg ketamine and 15 mg/kg xylazine and dorsal skinfold 
chambers were implanted, as previously described [46]. To avoid alterations of the microcirculation due 
to anesthesia or surgical trauma, the mice were allowed to recover from the implantation procedure for 
72 h. Subsequently, animals were treated with 5 mg/kg fascaplysin i.p. (n = 6) or vehicle i.p. (DMSO;  
n = 6) 19 h and 1 h before photochemically induced thrombus formation. The dose of 5 mg/kg fascaplysin 
has previously been shown in tumor studies to effectively inhibit tumor growth in vivo without inducing 
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toxic side effects [47,48]. In control experiments, animals were treated with an intravenous injection 
(i.v.) of 100 IU/kg heparin (n = 3) or vehicle (saline; n = 3) 15 min before photochemically induced 
thrombus formation. 
For in vivo microscopic observation, mice were immobilized on a Plexiglas stage and the dorsal 
skinfold chamber was attached to the microscopic stage. After retrobulbary i.v. injection of 0.05 mL  
5% FITC-labeled dextran 150,000 for contrast enhancement by staining of blood plasma, intravital  
epi-illumination fluorescence microscopy was performed using a Zeiss microscope (Zeiss, Oberkochen, 
Germany) with a 100 W mercury lamp attached to a blue filter. The microscopic images were recorded 
by a charge-coupled device video camera (FK6990; Pieper, Schwerte, Germany) and transferred to a 
monitor (Trinitron; Sony, Tokyo, Japan) and DVD system (DVD-HR775; Samsung, Eschborn, Germany) 
for off-line evaluation [31]. 
Using a ×20 long distance objective (Achroplan 0.50 W; Zeiss, Oberkochen, Germany), baseline 
blood flow was monitored in individual venules (diameter range: 15–25 μm; n = 4 per chamber). 
Subsequently, thrombus formation was photochemically induced by continuous local exposure of the 
vessels to filtered light (450–490/>520 nm excitation/emission wavelength) with a ×63 water immersion 
objective (Achroplan 0.95 W; Zeiss, Oberkochen, Germany) [41,49]. 
Quantitative off-line analyses of the microscopic images were performed using the software package 
CapImage (Zeintl, Heidelberg, Germany). Diameters, centerline RBC velocity and wall shear rate were 
determined in venules prior to thrombus induction. Diameters (d) were measured in μm perpendicularly 
to the vessel path. Centerline RBC velocity (v, given in μm/s) was analyzed using the line shift  
method [50] and wall shear rate (y, given in s−1) was calculated based on the Newtonian definition:  
y = 8 × v/d. The kinetics of thrombus formation was assessed by measuring the time (given in s) until 
sustained cessation of blood flow due to complete vessel occlusion. 
4.12. Tail-Vein Bleeding Time 
At the end of the dorsal skinfold chamber experiments, tail-vein bleeding time was determined as a 
parameter of primary hemostasis, as previously described [51]. Briefly, an incision was made over a 
lateral tail vein at a constant position of the tail. Subsequently, the tail was immersed in saline (37 °C). 
The time from incision to complete cessation of the blood stream was measured as bleeding time. At the 
end of the in vivo experiments, the animals were sacrificed with an overdose of the anesthetics. 
4.13. Statistical Analysis 
After testing the data for normal distribution and equal variance, differences between the groups were 
analyzed by the unpaired Student’s t-test (SigmaStat; Jandel Corporation, San Rafael, CA, USA).  
All values are expressed as means ± SEM. Statistical significance was accepted for a value of p < 0.05. 
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